Invited critical reviewUsefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management
Section snippets
Mechanism of drug-protein binding
Many drugs bind reversibly to plasma proteins mainly albumin and α1-acid glycoprotein. While drug binding to plasma protein was considered to represent an unspecific physiochemical phenomenon such as absorption of small molecules by activated charcoal, accumulation of evidence indicates that drug binding to serum proteins only occur at few binding sites on proteins.
Albumin is the most abundant protein in human serum with a molecular weight of 66,500 Da. X-ray diffraction study has demonstrated
Drugs which are candidate for free drug monitoring
If the protein binding of a drug is less than 80%, it is not considered as a candidate for free drug monitoring because variation in protein binding may not have clinically significant effect in altering free drug concentrations. An exception is free digoxin monitoring (digoxin is only 25% protein bound), which is very useful in patients overdosed with digoxin and being treated with digibind, the FAB fragment of anti-digoxin antibody. Protein binding of some commonly monitored therapeutic drugs
Historical perspective of free drug monitoring
The first comprehensive report demonstrating the clinical utility of free drug monitoring dated back to 1973 [11]. In a population of 30 epileptic patients, the authors found a better correlation with toxicity (in coordination, ataxia, and nystagmus) and free drug concentrations. Blum et al. described a uremic patient who was well controlled on a total phenytoin concentration of 3 μg/mL, which was far below the recommended therapeutic range of 10- to 20 μg/mL. [12]. Most likely cause of this
When should free anticonvulsant be monitored?
For strongly protein bound anticonvulsants, such as phenytoin, valproic acid and carbamazepine, free drug monitoring is strongly recommended in the following cases.
- 1.
Uremic patients
- 2.
Patients with chronic liver disease
- 3.
Patients with hypoalbuminemia (burn patients, elderly, pregnancy, AIDS etc.)
- 4.
Suspected drug–drug interactions where one strongly protein bound drug can displace another strongly protein bound anticonvulsant.
Saliva and tears: alternative to serum for therapeutic drug monitoring
Drugs, which are not ionizable or are un-ionized within the salivary pH range (phenytoin, carbamazepine, theophylline) are candidates for salivary therapeutic drug monitoring [117]. Salivary flow rate vary significantly both between individuals and under different conditions. The use of stimulated saliva has advantage over resting saliva. The salivary flow rate, pH and sampling condition and other pathophysiological factors may influence the concentration of a particular drug in saliva.
Assay techniques for free anticonvulsants
Ultrafiltration using Centrifree Micropartition System is the most common technique for monitoring free drug concentrations in clinical laboratories. Usually 0.8–1.0 mL of serum is centrifuged for 15–20 min to prepare the ultrafiltrates. Then free drug concentrations are measured in the protein free ultrafiltrates. The time of centrifuging to prepare ultrafiltrate is crucial for measuring free drug concentrations. Liu et al. demonstrated that there is a significant difference between measured
Pitfalls of using equations for predicting free phenytoin concentrations
Beck et al. compared free phenytoin concentrations predicted by three different equations with measured values. The authors used the Gugler method, Sheiner–Tozer equation and Sheiner–Tozer nomogram for predicting free phenytoin concentrations from measured total phenytoin concentrations and albumin concentrations. Authors concluded that all three methods for predicting free phenytoin concentrations suffered from bias and should not be used for predicting free phenytoin concentrations. The
Therapeutic drug monitoring of new anticonvulsants
Careful monitoring of liver function test and blood cell counts are strongly recommended for felbamate due to its known toxicity [127]. The suggested therapeutic range is 125–250 mmol/L. The drug is only 20–25% bound to serum protein and currently there is no indication for monitoring free felbamate level. There is no systematic study to establish a therapeutic range for gabapentene. A tentative target range of 70–120 μmol/L have been suggested. There are more indications for therapeutic
Conclusions
Therapeutic drug monitoring of strongly protein bound antiepileptic drugs such as phenytoin, valproic acid and carbamazepine is useful for patients with uremia, liver disease and hypoalbuminemia. Drug–drug interactions may also increase free fractions of antiepileptic drugs without significantly altering total drug concentrations. Monitoring free concentration of immunosuppressant drugs like cyclosporine, tacrolimus and mycophenolic acid may have clinical value but are not usually offered in
References (129)
- et al.
Crystallographic analysis reveals common modes of binding of medium and long chain fatty acids to human serum albumin
J Mol Biol
(2000) - et al.
Structural basis of the drug-binding specificity of human serum albumin
J Mol Biol
(2005) A molecular functional study on the interactions of drugs with plasma proteins
Drug Metab Pharmacokinet
(2005)- et al.
Time course of alpha 1 acid glycoprotein and its relation to myocardial enzymes after acute myocardial infarction
Am J Cardiol
(1985) - et al.
Factors affecting quinidine protein binding in humans
J Pharm Sci
(1984) - et al.
High unbound mycophenolic acid concentrations in a hematopoietic cell transplantation patient with sepsis and renal and hepatic dysfunction
Biol Blood Marrow Transplant
(2005) - et al.
Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry
J Chromatogr B Analyt Technol Biomed Life Sci
(2004) Free drug measurements: methodology and clinical significance
Clin Chim Acta
(1985)- et al.
Elevated free fatty acid concentrations in lipemic sera reduce protein binding of valproic acid significantly more than phenytoin
Am J Med Sci
(1997) - et al.
Protein binding of drugs in uremia and normal serum: the role of endogenous binding inhibitors
Biochem Pharmacol
(1976)
Phenytoin toxicity associated with hypoalbuminemia in critically ill patients
Chest
A molecular functional study on the interactions of drugs with plasma proteins
Drug Metab Pharmacokinet
Structural basis of drug-binding specificity of human serum albumin
J Mol Biol
Incidence and preventability of adverse drug events among older persons in the ambulatory settings
JAMA
Free drug monitoring
Clin Lab Med
Relationship between exposure and nonspecific binding of thirty three central nervous system drugs in mice
Drug Metab Dispos
Pharmacokinetics and bio-availability of sodium valproate
Clin Pharmacol Ther
Absorption and distribution of anti-epileptic drugs
Epilepsia
Atomic structure and chemistry of human serum albumin
Nature
Hydrophobic and ionic factors in binding local anesthetics to the major variant of human alpha 1 acid glycoprotein
Pharmacol Exp Ther
Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication
Epilepsia
Altered protein binding of diphenylhydantoin in uremic plasma
N Engl J Med
Br J Clin Pharmacol
Lidocaine plasma protein binding
Clin Pharmacol Ther
Diazepam and lidocaine plasma protein binding in renal disease
Clin Pharmacol Ther
Alpha 1-acid glycoprotein and plasma lidocaine binding
Clin Pharmacokinet
A free lignocaine index as a guide to unbound drug concentration
Br J Clin Pharmacol
Displacement of lidocaine from human plasma proteins by disopyramide
Pharmacol Toxicol
Caucasian versus African American differences in orosomucoid: potential implication for therapy
Pharmacotherapy
Binding of alfentanil to human alpha-1 glycoprotein, albumin and serum
Int J Clin Pharmacol
Distribution of cyclosporine in organ transplant recipients
Clin Pharmacokinet
Determination of cyclosporine in saliva using liquid chromatography-tandem mass spectrometry
Ther Drug Monit
Changes in tacrolimus distribution in blood and plasma protein binding following liver transplant
Ther Drug Monit
Factors affecting variability in distribution of tacrolimus in liver transplant recipients
Br J Clin Pharmacol
Intraindividual and interindividual variation in the pharmacokinetics of mycophenolic acid in liver transplant patients
J Clin Pharmacol
Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant
Br J Clin Pharmacol
Protein binding in antiretroviral therapies
AIDS Res Hum Retrovir
Indinavir plasma protein binding in HIV-1 infected adults
AIDS
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir
Ther Drug Monit
Determination of amprenavir total and unbound concentrations in plasma by high performance liquid chromatography and ultrafiltration
Ther Drug Monit
Lopinavir protein binding in vivo through 12-hour dosing interval
Ther Drug Monit
Fab antibody fragments: some applications in clinical toxicology
Drug Safety
Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays
Clin Chem
Digoxin and its related endogenous factors
Crit Rev Clin Lab Sci
Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS: 180
Ther Drug Monit
New enzyme-linked immunosorbent digoxin assay on the ADVIA IMS 800 I system is virtually free from interference of endogenous digoxin-like immunoreactive factors
Ther Drug Monit
Suppression of total digoxin concentration by digoxin-like immunoreactive substances in the MEIA digoxin assay: elimination of interference by monitoring free digoxin concentrations
Am J Clin Pathol
Digoxin assays: frequent substantial and potentially dangerous interference by spironolactone, canrenone and other steroids
Clin Chem
Lack of clinically significant interference by spironolactone with the AxSYM digoxin II assay
Ther Drug Monit
Simultaneous determination of bufadienolides in traditional Chinese medicine preparations, Liu-Shen-Wan by liquid chromatography
J Pharm Pharmacol
Cited by (135)
Combining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity
2023, Computer Methods and Programs in BiomedicineToward SERS-based therapeutic drug monitoring in clinical settings: Recent developments and trends
2023, TrAC - Trends in Analytical ChemistryDetection of antibody-conjugate payload in cynomolgus monkey serum by a high throughput capture LC–MS/MS bioanalysis method
2023, Journal of Pharmaceutical and Biomedical AnalysisPilot study of oral fluid and plasma meropenem and piperacillin concentrations in the intensive care unit
2021, Clinica Chimica ActaCitation Excerpt :Besides the binding of drugs to plasma proteins, diffusion of drugs into the oral fluid depends on the pH values of oral fluid as well as on the physicochemical properties of the compound itself. These physicochemical properties include the drug’s acid dissociation constant (pKa) value, molecular weight and lipophilicity (reflected by the octanol/water partition coefficient) [3,4]. The use of oral fluid in TDM has been studied for other drugs before, with oral fluid concentrations often showing no correlation with plasma concentrations (e.g., clozapine) [5].
How to design a study to evaluate therapeutic drug monitoring in infectious diseases?
2020, Clinical Microbiology and Infection